Please login to the form below
Pfizer/BioNTech
This page shows the latest Pfizer/BioNTech news and features for those working in and with pharma, biotech and healthcare.
Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
In the UK, the Pfizer/BioNTech is currently only approved for use to prevent COVID-19 in individuals aged 16 and over. ... In March, Pfizer and BioNTech revealed positive data for their vaccine in adolescents aged 12 to 15, both with or without prior
Latest news
-
EU asks AZ to deliver 120 million COVID-19 vaccines by the end of June
Instead, the EU will likely rely on the Pfizer/BioNTech vaccine, after signing a new contract to receive 1.8 billion doses of the jab for 2021 to 2023.
-
Emergency authorisation for Pfizer/BioNTech vaccine expanded in the US
The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for Pfizer/BioNTech’s COVID-19 vaccine to include adolescents aged 12 to 15. ... The new approval makes Pfizer/BioNTech’s COVID-19 vaccine the first to be
-
Pfizer, BioNTech file for full US approval of COVID-19 vaccine
Under the emergency use approval, Pfizer and BioNTech have delivered over 170 million doses of their vaccine across the US. ... Pfizer and BioNTech will also submit the ‘required’ manufacturing and facility data for the licensing of their vaccine in
-
China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine
Bahrain. In a statement, the WHO also added that the vaccine’s ‘easy storage requirements make it highly suitable for low-resource settings’, while other vaccines – such as Moderna and ... BioNTech’s mRNA-based jabs – carry requirements for
-
BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021
BioNTech’s chief executive officer (CEO) Ugur Sahin said the company is now on track to produce three billion doses of its Pfizer-partnered COVID-19 vaccine in 2021, an increase ... In March, BioNTech forecast significant sales of 9.8bn for its
EU asks AZ to deliver 120 million COVID-19 vaccines by the end of June
Emergency authorisation for Pfizer/BioNTech vaccine expanded in the US
Pfizer, BioNTech file for full US approval of COVID-19 vaccine
China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine
BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021
More from news
Approximately 52 fully matching, plus 105 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
In the UK, the looming Brexit sparked new models of regulatory approval and fast-track opportunities, as recently observed in the rapid approval of Pfizer’s COVID-19 vaccine. ... So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University
-
Working together against COVID-19
Beyond the connection between HCPs and pharma or NGOs, it is encouraging to see collaborations such as Clover and GSK evaluating a vaccine candidate and Pfizer and Biontech doing the same. ... A number of top pharma companies are included in the newly
Rare genetic diseases – what’s in store for 2021?
Working together against COVID-19
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
What does the COVID-19 vaccine mean for the future of R&D?
Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster.
-
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so
-
Mistrust in medical research: a patient perspective
Health Products Regulatory Agency’s speedy approval of the Pfizer-BioNTech COVID-19 vaccine in the UK. ... A good example is a recent incident in the UK that made headline news, where two NHS workers who were among the first to receive the
-
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. ... At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more
-
Hanover Communications
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection.
Hanover Communications
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
-
Associate Account Director
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Senior Medical Writer
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
